These findings align with the diverse functions of BAZ family members [5, 18, 19, 48], and provide mechanistic insights for future precision oncology approaches based on the corresponding BAZ1A, BAZ1B, BAZ2A and BAZ2B molecular signatures, akin to targeting tumors with high β-catenin plus high CCAR2 expression for increased survival in colorectal cancer patients [29]. This evidence concerns the gene PARD3 and colorectal cancer.